Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).

NCT00242775 Phase 3 COMPLETED

The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	2100
Start date	2005-05
Completion	2006-05

Conditions

• Asthma

Interventions

• Budesonide/formoterol Turbuhaler
• Salmeterol/fluticasone Diskus

Primary outcomes

• Time to first severe asthma exacerbation

Countries

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Malaysia, Mexico, Philippines, Singapore, South Africa, Spain, Thailand, Vietnam